<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100253</url>
  </required_header>
  <id_info>
    <org_study_id>IRFMN-RA-6453</org_study_id>
    <nct_id>NCT03100253</nct_id>
  </id_info>
  <brief_title>Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation</brief_title>
  <acronym>RAFTING</acronym>
  <official_title>Open-label, Randomized Controlled Trial Comparing Tocilizumab to Anti-TNF Treatment and Discovery of Biomarkers for Treatment Selection in Rheumatoid Arthritis Patients With Inadequate Response to a First Anti-TNF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of switching to a different molecular target (from TNF to IL6) versus
      cycling to a second TNF inhibitor in patients with active RA, who have not adequately
      responded to a previous treatment with a first anti-TNF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      New drugs for the treatment of rheumatoid arthritis (RA) with action on specific molecular
      target (e.g. anti-TNF) have improved the prognosis of patients with an inadequate response to
      conventional therapy such as methotrexate (MTX).

      However, approximately 50% of patients treated with first-line anti-TNF discontinue treatment
      after two years due to ineffectiveness or adverse events. The second line treatment involves
      the use of another anti-TNF drug or switching to a different molecular target (anti-IL6,
      -CD20 or CTLA-4-Ig) in combination with MTX.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with good EULAR</measure>
    <time_frame>24 weeks</time_frame>
    <description>the proportion of patients with good EULAR response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a good/moderate EULAR</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of patients with a good/moderate EULAR response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a good/moderate EULAR</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients with a good/moderate EULAR response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ACR20/50/70 response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of patients with ACR20/50/70 response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ACR20/50/70 response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients with ACR20/50/70 response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a remission according to DAS28/SDAI/CDAI</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients with a remission according to DAS28/SDAI/CDAI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a remission according to DAS28/SDAI/CDAI</measure>
    <time_frame>48 weeks</time_frame>
    <description>Proportion of patients with a remission according to DAS28/SDAI/CDAI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a remission according to DAS28/SDAI/CDAI</measure>
    <time_frame>96 weeks</time_frame>
    <description>Proportion of patients with a remission according to DAS28/SDAI/CDAI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Van Der Heijde Modified Total Sharp Score [X-ray score]</measure>
    <time_frame>48 weeks</time_frame>
    <description>Van Der Heijde Modified Total Sharp Score [X-ray score]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Van Der Heijde Modified Total Sharp Score [X-ray score]</measure>
    <time_frame>96 weeks</time_frame>
    <description>Van Der Heijde Modified Total Sharp Score [X-ray score]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire (HAQ) score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Health Assessment Questionnaire (HAQ) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire (HAQ) score</measure>
    <time_frame>48 weeks</time_frame>
    <description>Health Assessment Questionnaire (HAQ) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire (HAQ) score</measure>
    <time_frame>96 weeks</time_frame>
    <description>Health Assessment Questionnaire (HAQ) score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>&quot;Switching&quot; strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tocilizumab [RoActemra®] [ATC: L04AC07] 8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Cycling&quot; strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab OR
Infliximab, adalimumab, golimumab or certolizumab if initial failure to the receptor fusion protein, etanercept.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days</description>
    <arm_group_label>&quot;Switching&quot; strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>a. Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab</description>
    <arm_group_label>&quot;Cycling&quot; strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>infliximab if initial failure to the receptor fusion protein, etanercept.</description>
    <arm_group_label>&quot;Cycling&quot; strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>adalimumab if initial failure to the receptor fusion protein, etanercept.</description>
    <arm_group_label>&quot;Cycling&quot; strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Golimumab</intervention_name>
    <description>golimumab if initial failure to the receptor fusion protein, etanercept.</description>
    <arm_group_label>&quot;Cycling&quot; strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certolizumab Pegol</intervention_name>
    <description>Certolizumab Pegol if initial failure to the receptor fusion protein, etanercept.</description>
    <arm_group_label>&quot;Cycling&quot; strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years at the time of signing the informed consent form and either male or
             female.

          -  Diagnosis of RA according to the 1987 ACR classification criteria OR 2010 ACR/EULAR
             classification criteria at least 6 months prior to screening.

          -  Patients with persistent RA disease activity whilst being treated with an initial TNFi
             agent on a background MTX up to 20-25 mg/week for at least 12 weeks defined according
             to SIR and EULAR guidelines as: primary non-response: failing to improve DAS28 by ≥
             1.2 or failing to achieve DAS28 ≤ 3.2 within the first three to six months of starting
             the initial TNFi; secondary non-response: determined by physician decision with
             evidence of flare and deterioration in DAS28 of ≥ 1.2.

          -  Methotrexate (MTX) dose stable for 28 days prior to screening.

          -  Patients on NSAIDs and / or corticosteroids must remain on an unchanged regimen for at
             least 28 days prior to study drug administration.

          -  The patient must be able to comply with the study visit schedule and other protocol
             requirements.

          -  The patient understands the purpose of the study and is able and willing to sign the
             informed consent form, according to ICH/GCP.

          -  Signed written informed consent for biological analysis.

          -  Female patients with reproductive potential must have a negative serum pregnancy test
             within 7 days prior to start of trial. Women of childbearing potential and male
             patients must be willing to practice acceptable methods of contraception during
             treatment and for 6 months (female patients) and 3 months (male patients) after
             discontinuation of treatment.

        Exclusion Criteria:

          -  Patients who have previously received more than 1 TNFi drug OR any other biological
             therapy.

          -  Patients with inflammatory joint disease of different origin or any arthritis with
             onset prior to 16 years of age.

          -  Patients taking any disease-modifying antirheumatic drug (DMARDs) (e.g. all except
             methotrexate). Discontinuation must occur at least 28 days prior to study treatment
             start.

          -  History or presence of other disease, metabolic dysfunction, physical examination
             finding, or clinical laboratory finding giving reasonable suspicion of a disease or
             condition that contraindicates the use of an investigational drug.

          -  Known hypersensitivity to any active substance or excipients of study drug.

          -  Pregnancy or breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauro Galeazzi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria alle Scotte</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlo Scirè</last_name>
    <phone>+390239014519</phone>
    <email>c.scire@reumatologia.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Roberto</last_name>
    <phone>+390239014648</phone>
    <email>anna.roberto@marionegri.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Consorziale Ospedaliera Policlinico</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florenzo Iannone</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale - Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimiliano Limonta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nazzarena Malavolta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Centrale di Bolzano</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernd Raffeiner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosario Foti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera-Universitaria S.Anna c/o Nuovo Arcispedale S. Anna</name>
      <address>
        <city>Cona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcello Govoni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicoletta Romeo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università di Firenze</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Matucci Cerinic</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Di Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianfilippo Bagnato</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Gaetano Pini</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pier Luigi Meroni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Sebastiani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Monserrato</name>
      <address>
        <city>Monserrato</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Mathieu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asl Napoli 1 centro</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enrico Tirri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alarico Ariani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Caporali</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo Forlanini</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giandomenico Sebastiani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo F Selmi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale SS Annunziata</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Passiu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Città della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enrico Fusaro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Chiara</name>
      <address>
        <city>Trento</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Paolazzi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine Sanata Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salvatore De Vita</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona - Policlinico GB Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maurizio Rossini</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Tocilizumab</keyword>
  <keyword>anti-TNF treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Certolizumab Pegol</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

